Prot #D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II Lymph-node Negative

Project: Research project

StatusActive
Effective start/end date12/20/1912/20/22

Funding

  • AstraZeneca Pharmaceuticals LP (Prot #D9103C00001)